European Heart Journal - Cardiovascular Pharmacotherapy

Topic(s):

Cardiovascular Pharmacology and Pharmacotherapy

Specific focus on clinical cardiovascular pharmacology

Why a new journal?

Pharmacology is an extremely important part of cardiology today. Nearly every patient with cardiac disease is on some kind of medication. Already there are almost half a million references to ‘cardiovascular pharmacology’ in MEDLINE and the number of papers within this area is growing very fast. More studies are needed to improve outcomes of patients with cardiovascular disease, which is the most common cause of death globally.

Mission Statement:

The official journal of the ESC Working Group on Cardiovascular Pharmacotherapy and a brand new addition to the ESC Journal Family, EHJ - Cardiovascular Pharmacotherapy aims to publish reports specifically describing clinical research relevant to cardiovascular drug therapy.

Contribute to the success of this brand new journal

Submit your paper

Visit the journal's home page

EHJ: Cardiovascular Pharmacotherapy information

ISSN 2055-6837
Volume 3 - year 2017
4 issues

2017 Public price

173 EUR

2017 Special rates

Members of the Working Group on Cardiovascular Pharmacotherapy
Online: access included in the Membership
Combined (print & online): 103.80 EUR

ESC Constituent Bodies Members
Combined (print & online): 103.80 EUR

ESC Professional/ Professional Plus Members
Combined (print & online): 77.85 EUR

Subscribe here

Editor-in-Chief

Professor Stefan Agewall, (NO), MD PhD, FESC, FACC, is a senior consultant and professor of cardiology at Oslo University Hospital. More than 170 peer-reviewed publications in the cardiovascular field. Chairman of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology 2014-2016. Senior Consulting Editor of the European Heart Journal. Board member of the European Society of Cardiology Committee for Practice Guidelines and Editorial board member of the European Heart Journal.

Most recent articles from EHJ-CVP

Date

Title

Topic(s)

Date: 12 Jun 2017

Title: Metabolic control, anticoagulation, and gender aspects
Date: 24 Apr 2017

Title: Comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.
Date: 24 Apr 2017

Title: Response to the ‘Comment on the editorial by Turner et al. on Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al. ’
Date: 24 Apr 2017

Title: Response to comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.
Date: 20 Apr 2017

Title: Geographical differences in prescription of secondary preventive drug therapy after acute myocardial infarction in Norway
Date: 17 Mar 2017

Title: Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry
Date: 13 Mar 2017

Title: Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a viewpoint
Date: 28 Feb 2017

Title: Gender differences in the effects of cardiovascular drugs
Date: 16 Feb 2017

Title: Digoxin: beneficial or harmful?
Date: 01 Feb 2017

Title: Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists
Date: 08 Nov 2016

Title: Thiazolidinediones are associated with a decreased risk of atrial fibrillation compared with other antidiabetic treatment: a nationwide cohort study
Date: 27 Sep 2016

Title: Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes

Show navigation Hide navigation